SQSTM1 and cancer: However, given their crosstalk, targeting p62 or NRF2 may influence each other and, consequently, both represent potential druggable targets in cancers with p62 and NRF2 overexpression to also improve the anti-cancer therapies through reactivation of the p53 oncosuppressor function [13,29].